About HIV/AIDS
HIV infection, which can lead to AIDS, is a pandemic that can affect anyone, regardless of race, gender, age, or sexual orientation. 33 million people are currently infected globally; it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, more than a million people in the U.S. have contracted the virus. Every 9 1/2 minutes, someone in the U.S. is infected with HIV. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B and C. GeoVax vaccines are currently designed to function against clade B.
For more Information, please visit www.geovax.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
GEOVAX LABS, INC. Statements of Operations Data (amounts in thousands, except per share data) Year Ended December 31, ------------------------ 2012 2011 ----------- -----------Grant Revenue $ 2,657 $ 4,899Operating expenses: Research and development 3,043 4,276 General and administrative 1,753 2,972 ----------- ----------- 4,796 7,248 ----------- -----------Loss from operations (2,139) (2,349)Interest income 4 2 ----------- -----------Net loss $ (2,135) $ (2,347) =========== ===========Net loss per common share $ (0.12) $ (0.15) =========== ===========Weighted averages shares outstanding 18,316 15,736 Balance Sheet Data (amounts in thousands) December 31, ------------------------ 2012 2011 ----------- -----------Cash and cash equivalents $ 1,036 $ 1,168Working capital 1,017 476Total assets 1,478 1,645Deficit accumulated during the development stage (24,767) (22,632)Total stockholders' equity 1,151 704
CONTACT
Dian Griesel, Inc.
Tom Caden
Investor Relations
Susan Forman or Laura Radocaj
Public Relations
212-825-3210
